Skip to main content

Table 1 IC50 values of anthraquinone derivatives (compound 1–5) on various skin cancer cells (SK-MEL5 and B16F10) and breast cancer cells (MCF7 and MBA-MD-231)

From: Cytotoxic properties of the anthraquinone derivatives isolated from the roots of Rubia philippinensis

Compounds IC50 (μM)a  
SK-MEL-5 B16F10 MCF7 MDA-MB-231 MDCK
1 91.04 ± 1.88 48.68 ± 0.10 65.48 ± 1.10 49.44 ± 0.78 192.34 ± 0.49
2 46.75 ± 1.39 77.88 ± 0.34 79.96 ± 1.14 59.22 ± 0.40 168.76 ± 0.61
3 53.08 ± 0.30 98.79 ± 2.10 49.17 ± 0.85 48.64 ± 0.33 199.32 ± 1.88
4 21.35 ± 0.99 23.71 ± 1.71 15.75 ± 1.00 14.65 ± 1.45 67.89 ± 1.02
5 42.79 ± 1.32 29.48 ± 2.61 24.10 ± 1.06 13.03 ± 0.33 79.01 ± 0.03
Oxaloplatin 14.25 ± 1.02 10.51 ± 0.92 8.59 ± 1.22 7.95 ± 1.92 24.02 ± 1.04
  1. aThe values are mean ± standard deviation. IC50 (concentration inhibiting 50% growth). SK-MEL-5 (human melanoma); B16F10 (murine melanoma); MCF-7 (human breast adenocarcinoma); MDA-MB-231 (human breast adenocarcinoma), MDCK (normal kidney epithelial cells)